Ann: 1st patient dosed in Phase 1b recurrent glioblastoma trial, page-11

"...second line therapy..."

That's a huge achievement, shows that apart of chemo, and limited radiation and surgery, nothing better is available atm. IMU's Azer-Cel has been celebrated as 3rd line of defense with some expectations to become 2nd line in the future.

Market reacted on Tuesday by taking an IND for a drug approval and is subdued due to the RI but more due to having no idea what 2nd line means.

Can't blame them, until recently I had no idea either.

IND is a huge achievement too and can be sold / transferred to other parties. 2 years ago it would have been valued at $100m and higher due to CD19 CAR-T analogy and success. But again market unaware of the potential advantage CD17 has over CD19 when it comes to solid cancers.

When CD19 CAR-Ts were developed and approved a lot of problems regarding safety, logistics and efficacy appeared - nothing unusual with brand new technologies. But using that knowledge developing CD17 CAR-T by the ones who actually developed CD19 CAR-T has helped remove those problems. Of course new ones will come to light but at least the known ones have been addressed - again, a fact ignored by the market and not considered by the 2.8c.


Twice trading in the 4c range shows that 2.8c is way too cheap. If SH would use extra funds to participate in the RI and not selling CHM to fund it then the RI at 2.8c would be a great sign of appreciation of sh loyalty by the board. But knowing that this won't be the case it actually becomes a selling of CHM to PH and his mates / extended beneficiaries if retail won't take up their entitlements. Hopper could easily end up owning 51% after the RI, at 2.8c an absolute steal.

As assumed at IMU too, the more shares PH holds the lower he could agree to a t/o or deals. The extreme discounts at IMU, CHM and this week at RAD despite the fantastic progress at all 3 companies seem to confirm his strategy. While he and probably the CEO's - maybe not their first goal working here - will end up well rewarded LT sh could be left in the rain.

CHM 1101 and 2101 had great progress announcements for an EV almost ZERO, and that hasn't taken into account the NK-cell platform targeting solid cancers in human trials.

SH can only hope that the chairman's action are really focused to benefit all sh not just him and his big mates.

Often companies' techs / products / service suck and have no future. Here the opposite is the case but the chairman's actions are contradicting every great announcement.


Time will tell whether my assumptions are false or correct.

I have sold out this week mid 4c as it became clear that people mixed up IND with Drug approval. I am still entitled to the offer - again so many got those cut off dates wrong - and will wait to the end to decide, probably 1 week extension as at IMU and before that here at CHM.

Normally an easy decision to walk away based on PH - if there weren't the compelling science and people driving it forward.

GLTA